Mark Mcdade - Jun 4, 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
Director
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Stock symbol
TRML
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/6/2025, 04:30 PM
Previous filing
Jun 7, 2024
Next filing
Oct 28, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MCDADE MARK Director C/O QIMING U.S. VENTURES MANAGEMENT, LLC, 11100 NE 8TH ST., SUITE 200, BELLEVUE /s/ Brad Middlekauff, Attorney-in-Fact 2025-06-06 0001242126

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRML Stock Option (Right to Buy) Award $0 +16.8K $0.00 16.8K Jun 4, 2025 Common Stock 16.8K $18.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.